Observation of preemptive analgesia of tramadol hydrochloride sustained-release tablets for cutaneous venous malformation polidocanol sclerotherapy / 中华整形外科杂志

ABSTRACT

Objective@#To investigate the clinical effect and safety of tramadol hydrochloride sustained-release tablets for subcutaneous venous malformation polidocanol sclerotherapy.@*Methods@#The experimentation was designed in block randomization. 106 patients with subcutaneous venous malformations from May 2016 to November 2017, which in line with the inclusion criteria, were randomly divided into experimental group and control group, with 53 cases in each group. Experimental group patients took 100 mg tramadol hydrochloride sustained-release tablet 1 hour before operation, while control group patients took nothing. Both group underwent polidocanol foam injection therapy guided by the color ultrasound, to observe the effect of operative analgesia, postoperative analgesia (VAS grade) and complications. The data was analyzed by SPSS 19.0 software. Comparison between two groups was done with independent sample t test and P<0.05 was considered statistically significant.@*Results@#The pain sensation(VAS grade) in surgery in experimental group(3.02±1.118)were significantly reduced than control group(6.30±1.514) (t=-12.701, P=0.000). 2 hours after operation the pain sensations decreased in both groups, but experimental group(0.23±0.577)were still better than which in control group(0.60±0.987)(t=-2.403, P=0.018). Three patients of experimental group(5.7%) felt mild nausea, and no other severe complications nor adverse effects occured.@*Conclusions@#Oral tramadol hydrochloride sustained-release tablets is one of safe, simple and effective way to achieve satisfactory preemptive analgesia for venous malformation polidocanol foam sclerotherapy.